Source - Alliance News

-Oxford Nanopore Technologies PLC on Friday said its sequencing technology has been selected for the 1000 Genomes Project, led by University of Washington and Seattle Children’s Hospital.

Oxford Nanopore is an Oxford, England-based life sciences company that develops nanopore sequencing products. The Oxford University spin-out focuses on the technology commercialisation of DNA and RNA strand sequencing.

It said its sequencing technology has been selected for use by researchers at the University of Washington and Seattle Children’s Hospital. The technology will be used by the 1000 Genomes Project initially to sequence 500 of the project’s samples.

The project’s goal ‘is to gain more scientific insights from the comprehensive genomic dataset and to create a catalogue of structural variation from a diverse set of individuals,’ Oxford Nanopore said.

Evan Eichler, professor of Genome Sciences at the University of Washington said: ‘Long-read sequencing is discovering potential disease-causing structural variations that were previously missed by short reads. The challenge is interpreting these variants of unknown significance. Having a database of structural variants from unaffected diverse controls is key to pinpointing to the disease-causing events.’

Oxford Nanopore shares were up 3.1% at 262.50 pence each on Friday morning in London. The stock debuted in London back in September at 425p, so is down 38% since then.

Copyright 2022 Alliance News Limited. All Rights Reserved

Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account. AJBell logo

Related Charts

Oxford Nanopore Technologies PLC (ONT)

-5.50p (-4.33%)
delayed 18:10PM